Date of Presentation
5-2-2024 12:00 AM
College
Rowan-Virtua School of Osteopathic Medicine
Poster Abstract
Autoimmune diseases are prevalent disorders that many individuals within the United States suffer from. Systemic lupus erythematosus (SLE) is a common autoimmune disease that has a high incidence in women of child-bearing age. Management for lupus depends on the anatomical location SLE manifests, the severity of disease, and the tolerance that one has for certain adverse effects. Glucocorticoids are commonly used to manage lupus. Currently, long term glucocorticoid usage is associated with devastating adverse effects, so current treatment options aim to mitigate corticosteroids use to improve quality of life while maintaining favorable health outcomes. New management for SLE include biologics such as Belimumab which offer improved health outcomes and decreased adverse effects. This research aims to explore the treatment options offered for lupus and demonstrate the benefits of Belimumab in patients with SLE. This review utilized the resources available from JAMA, PubMed, and ScienceDirect as primary databases. Clinical trials show that Belimumab is effective at mitigating clinical manifestations of SLE and slowing disease progression while also decreasing lupus flares that necessitate glucocorticoid treatments. Decreased usage of corticosteroids within SLE management improves quality of life by decreasing prevalent adverse effects. The goal of this review is to show that Belimumab should be considered early in treatment regimens for SLE patients to decrease adverse health outcomes and avoid long term side effects from current treatment options. This review should demonstrate the benefits that come with Belimumab, while also considering adverse effects and barriers that come with healthcare costs associated with SLE treatment.
Keywords
Systemic lupus erythematosus, Belimumab, Autoimmune Diseases, Disease Management, glucocorticoids, health outcomes, Treatment Outcome, Quality of Life
Disciplines
Health and Medical Administration | Immune System Diseases | Medicine and Health Sciences | Pharmaceutical Preparations | Primary Care | Rheumatology | Skin and Connective Tissue Diseases | Therapeutics
Document Type
Poster
DOI
10.31986/issn.2689-0690_rdw.stratford_research_day.93_2024
Included in
Health and Medical Administration Commons, Immune System Diseases Commons, Pharmaceutical Preparations Commons, Primary Care Commons, Rheumatology Commons, Skin and Connective Tissue Diseases Commons, Therapeutics Commons
A Systematic Review on Belimumab’s Effectiveness, Improved Health Outcomes and Quality of Life in Patients with Lupus Syndromes
Autoimmune diseases are prevalent disorders that many individuals within the United States suffer from. Systemic lupus erythematosus (SLE) is a common autoimmune disease that has a high incidence in women of child-bearing age. Management for lupus depends on the anatomical location SLE manifests, the severity of disease, and the tolerance that one has for certain adverse effects. Glucocorticoids are commonly used to manage lupus. Currently, long term glucocorticoid usage is associated with devastating adverse effects, so current treatment options aim to mitigate corticosteroids use to improve quality of life while maintaining favorable health outcomes. New management for SLE include biologics such as Belimumab which offer improved health outcomes and decreased adverse effects. This research aims to explore the treatment options offered for lupus and demonstrate the benefits of Belimumab in patients with SLE. This review utilized the resources available from JAMA, PubMed, and ScienceDirect as primary databases. Clinical trials show that Belimumab is effective at mitigating clinical manifestations of SLE and slowing disease progression while also decreasing lupus flares that necessitate glucocorticoid treatments. Decreased usage of corticosteroids within SLE management improves quality of life by decreasing prevalent adverse effects. The goal of this review is to show that Belimumab should be considered early in treatment regimens for SLE patients to decrease adverse health outcomes and avoid long term side effects from current treatment options. This review should demonstrate the benefits that come with Belimumab, while also considering adverse effects and barriers that come with healthcare costs associated with SLE treatment.